- SpaceX (SPCX.US) reported Q2 2026 revenue of $7.8 billion, while the market expected $6.934 billion.
- International oil prices experienced a significant decline on August 4. By the close of trading that day, the price of light crude oil futures for September delivery on the New York Mercantile Exchange fell by $4.57 to $75.77 per barrel, a decrease of 5.69%. Brent crude oil futures for October delivery on the London Exchange dropped by $4.41 to $79.36 per barrel, a decrease of 5.26%. This price correction was mainly driven by multiple bearish factors, with heightened market concerns over crude
- SpaceX (SPCX.US) reported total capital expenditures of $18.369 billion and a net loss of $541 million in Q2.
- Global stock market indices, Americas market closing updates
- Dianthus Therapeutics Q2 net loss widens as R&D costs rise
- Gilead Q2 FY26 loss per share widens to $(8.45); revenue rises 10% to $7.8 billion
- OneSpan Q2 FY26 net income falls 18.2% to $6.8 million; revenue rises 1% to $60.5 million
- Transcat FY27 Q1 net income drops 59.2% to $1.33 million; revenue rises 21.6% to $92.9 million
- BRIEF-Hackett Group Q2 Adjusted EPS USD 0.34
- Simulations Plus Chief Revenue Officer John Anthony DiBella II sells 1,000 shares for $18,280
- Coupang Q2 FY26 net loss widens to $570 million; revenue rises 4% to $8.86 billion
- Rigel Q2 FY26 net income falls to $17.3 million; revenue drops to $78.7 million
- BRIEF-Angi Inc. Q2 Revenue USD 248 Million Vs. IBES Estimate USD 251.5 Million
- Pebblebrook Co-President, CIO Thomas Charles Fisher sells 40,000 shares for $770,120.00
- Marriott Vacations Worldwide names Vladimir Anokhin chief strategy, transformation officer
- Arrowhead net loss widens to $194.28 million in FY26 Q3; revenue rises to $75.25 million
- Travere Q2 FY26 net loss widens to $34.8 million; FILSPARI net sales rise 96% year-over-year to $141.1 million
- ADI Global Distribution initial beneficial ownership filing names CD&R Investment Associates XII as 10% owner
- Irani Papel e Embalagem sets R$ 7.9 million interim dividend at R$ 0.03 per share
- BRIEF-LoanDepot Q2 EPS USD -0.02
- Teladoc Health director Mark V. Anquillare files initial beneficial ownership statement
- BRIEF-Pinterest Q2 Revenue USD 1,179.654 Million Vs. IBES Estimate USD 1,149 Million
- trivago Q2 FY26 net loss narrows 20% to EUR 5.2 million; revenue rises 21% to EUR 168.4 million
- US, UK reaffirm support for stablecoins, tokenization in joint financial regulation talks
- Freeport-McMoRan declares R$ 0.17 per unit distribution, payable Aug. 7
- Dianthus Q2 FY26 net loss widens to $50.22 million; R&D expenses climb 85.47% to $48.69 million
- Healwell AI schedules Q2 2026 results conference call and webcast
- Fennec Pharmaceuticals former director Rosty Raykov disposes of 10,000 common shares worth $95,800
- Milestone Pharmaceuticals schedules Q2 financial results call and business update
- BRIEF-Paylocity Q4 Net Income USD 60.3 Million
- BRIEF-Procept Biorobotics Q2 Revenue USD 94.498 Million Vs. IBES Estimate USD 92.9 Million
- BRIEF-Astera Labs Q2 Adjusted EPS USD 0.8 Vs. IBES Estimate USD 0.69
- Angi Q2 FY26 turns to net loss of $230.7 million; revenue falls 11% to $248 million
- BRIEF-Interparfums Inc Q2 EPS USD 0.95
- BRIEF-Teradata Q2 Adjusted EPS USD 0.69 Vs. IBES Estimate USD 0.56
- BRIEF-Postal Realty Trust Q2 Net Income USD 6.403 Million
- BRIEF-OrthoPediatrics Q2 EPS USD -0.3
- BRIEF-Digital Turbine Q1 Adjusted EPS USD 0.19
- BRIEF-Blackline Q2 EPS USD 0.27
- BRIEF-WEYCO Q2 Sales USD 62.2 Million
- BRIEF-Transmedics Group Q2 EPS USD 0.41
- BRIEF-Compass Inc Q2 EPS USD 0.11
- BRIEF-Flotek Industries Q2 Net Income USD 9.953 Million
- BRIEF-Booking Holdings Q2 Net Income USD 2,000 Million
- Rhythm Pharma executives to speak at Canaccord Genuity Growth Conference fireside chat
- Kratos Q2 FY26 adjusted EPS rises 90.91% to $0.21; revenue climbs 30.5% to $458.8 million
- Bed Bath & Beyond shifts listing to Nasdaq as NXH on Aug. 17 after NYSE exit Aug. 14
- Chefs' Warehouse markets new $625 million term loan for refinancing
- BRIEF-Revolve Q2 EPS USD 0.26
- Fulton Financial SEVP, CIO Angela M. Sargent sells 12,562 shares worth $311,991.93
- G. Willi-Food targets Aug. 26 as last trading day on Nasdaq ahead of Tel Aviv-only listing
- MGIC Investment President, COO Salvatore Miosi sells 30,000 shares for $891,000
- Atomera Q2 FY26 net loss widens to $6.3 million; revenue rises to $158,000
- Check Point CFO Golan Roei disposes of common shares worth $1.22 million
- FRP Holdings Q2 FY26 swings to net loss of $259,000; revenue rises 2.1% to $11.08 million
- BRIEF-Credit Acceptance Q2 Adjusted EPS USD 12.12
- BRIEF-Green Thumb Industries Q2 Revenue USD 306.7 Million Vs. IBES Estimate USD 299.1 Million
- BRIEF-Niagen Bioscience Inc Q2 Net Income USD 963 Thousand
- Diamondback Energy director Charles Alvin Meloy reports disposal of 33,333 common shares worth $6.62 million
- Genesco names Jonathan M. Collins SVP finance, CFO in initial beneficial ownership filing
- Paramount Skydance Q2 FY26 adjusted EBITDA rises 27% Y/Y to $1.1 billion
- Inception Growth Acquisition announces special shareholder meeting
- Praxis Precision Medicines grants 7,318 RSUs to 29 new employees under 2024 inducement plan
- STAAR Surgical schedules Q2 earnings call, webcast
- BRIEF-Red Rock Resorts Q2 Revenue USD 510.262 Million Vs. IBES Estimate USD 502.1 Million
- BRIEF-Transcat Q1 EPS USD 0.14
- BRIEF-Atomera Q2 Basic EPS USD -0.17
- BRIEF-Pacira Biosciences Q2 Revenue USD 192.4 Million Vs. IBES Estimate USD 190.8 Million
- BRIEF-Flywire Q2 Revenue USD 167.7 Million Vs. IBES Estimate USD 157.1 Million
- BRIEF-Wynn Q2 Adjusted EPS USD 1.24 Vs. IBES Estimate USD 1.11
- BRIEF-Personalis Q2 Net Income USD -31.683 Million
- BRIEF-Gilead Sciences Inc Q2 Adjusted EPS USD -6.75 Vs. IBES Estimate USD -7.24
- BRIEF-Lumen Technologies Q2 Adjusted EPS USD -0.07 Vs. IBES Estimate USD -0.14
- BRIEF-Bed Bath & Beyond Q1 Net Income USD -39.497 Million
- BRIEF-OneSpan Q2 Revenue USD 60.5 Million Vs. IBES Estimate USD 58.3 Million
- BRIEF-Travere Therapeutics Q2 EPS USD -0.37
- BRIEF-Allegiant Travel Q2 Adjusted EPS USD 2.19 Vs. IBES Estimate USD 1.14
- BRIEF-Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million
- BRIEF-Arrowhead Pharmaceuticals Q3 EPS USD -1.36
- Robert Half declares Q3 2026 distribution of R$ 2.02 per unit, payable Sept. 21
- Textron announces Q3 dividend of R$ 0.06 per unit
- Paycom Software declares BRL 0.04 per unit distribution for 3Q 2026, payable Sept. 14
- Eagle Materials announces Q3 2026 distribution of R$ 0.05 per unit, payable Oct. 19
- BRIEF-Booking Holdings Q2 Adjusted EPS USD 2.54 Vs. IBES Estimate USD 2.45
- Booking Holdings Q2 2026 GAAP net income more than doubles to $2 billion; revenue rises 8% to $7.4 billion
- BRIEF-Crexendo Q2 Revenue USD 24.6 Million Vs. IBES Estimate USD 24.6 Million
- Pacira BioSciences 2Q Adj EPS 73c >PCRX
- Pacira BioSciences 2Q Rev $192.4M >PCRX
- Pacira BioSciences 2Q EPS 12c >PCRX
- Lumen Technologies 2Q Adj Loss/Shr 7c >LUMN
- Syndax Pharmaceuticals 2Q Loss/Shr 55c >SNDX
- Pacira BioSciences 2Q Net $4.65M >PCRX
- Lumen Technologies 2Q Rev $2.81B >LUMN
- Lumen Technologies 2Q Loss/Shr 20c >LUMN
- Syndax Pharmaceuticals 2Q Loss $49.4M >SNDX
- Gilead Sciences 2Q Adj Loss/Shr $6.75 >GILD
- Gilead Sciences 2Q Loss/Shr $8.45 >GILD
- Gilead Sciences Sees FY Loss/Shr $3.75-Loss $3.40 >GILD
- Gilead Sciences 2Q Total Liver Disease Sales $877M >GILD
- Arrowhead Pharmaceuticals Signed an Agreement With Undisclosed Third Party >ARWR
